Articles related to ADJUVANT TREATMENT

Explore the detailed findings of a recent study that highlights the impact of treatment interruptions on survival rates in triple-negative breast cancer patients undergoing adjuvant radiotherapy.

Explore the intricacies of squamous-cell carcinoma of the skin treatment, from the role of adjuvant therapy to the importance of close clinical surveillance, particularly in immunosuppressed patients.

Pivotal Role of Adjuvant Osimertinib in EGFR-Mutated NSCLC Survival A groundbreaking phase 3 trial reveals the significant impact of adjuvant osimertinib on overall survival rates in patients with resected, EGFR-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC). “Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.” ADAURA ClinicalTrials.gov number, NCT02511106

Event-free survival was significantly longer in patients with resectable stage III or IV melanoma who received pembrolizumab both before and after surgery than in those who received adjuvant pembrolizumab alone. New toxic effects were not discovered.

An earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy showed that the addition of pembrolizumab to neoadjuvant chemotherapy resulted in a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery. The trial’s main findings on event-free survival have not been published.

The researchers tested whether a ctDNA-guided strategy could lower the need for adjuvant chemotherapy without increasing the risk of recurrence. Recurrence-free survival at 2 years was the main efficacy end objective. Adjuvant chemotherapy usage was a significant secondary end goal.